{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:44Z","timestamp":1791207344578,"version":"4.1.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,18]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with chronic lymphocytic leukemia (CLL). The initial results showed that ibrutinib-containing regimens had superior progression-free survival (PFS) and rituximab did not add additional benefits. Here we present an updated analysis. With a median follow-up of 55 months, the median PFS was 44 months (95% confidence interval [CI], 38-54) for BR and not yet reached in either ibrutinib-containing arm. The 48-month PFS estimates were 47%, 76%, and 76% for BR, ibrutinib, and IR, respectively. The benefit of ibrutinib regimens over chemoimmunotherapy was consistent across subgroups of patients defined by TP53 abnormalities, del(11q), complex karyotype, and immunoglobulin heavy chain variable region (IGHV). No significant interaction effects were observed between the treatment arm and del(11q), the complex karyotype, or IGHV. However, a greater difference in PFS was observed among the patients with TP53 abnormalities. There was no difference in the overall survival. Notable adverse events with ibrutinib included atrial fibrillation (afib) and hypertension. Afib was observed in 11 patients (pts) on BR (3%) and 67 pts on ibrutinib (18%). All-grade hypertension was observed in 95 pts on BR (27%) and 263 pts on ibrutinib (55%). These data show that ibrutinib regimens prolong PFS compared with BR for older patients with treatment-na\u00efve CLL. These benefits were observed across subgroups, including high-risk groups. Strikingly, within the ibrutinib arms, there was no inferior PFS for patients with abnormalities in TP53, the highest risk feature observed in CLL. These data continue to demonstrate the efficacy of ibrutinib in treatment-na\u00efve CLL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023021959","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T16:33:50Z","timestamp":1705077230000},"page":"1616-1627","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"first","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-7150","authenticated-orcid":false,"given":"Gabriela","family":"Perez Burbano","sequence":"additional","affiliation":[{"name":"2Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center, Columbus, OH"},{"name":"2Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecelia","family":"Miller","sequence":"additional","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyla A.","family":"Heerema","sequence":"additional","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wall","sequence":"additional","affiliation":[{"name":"2Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"4Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[{"name":"5Duke Cancer Institute, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-401X","authenticated-orcid":false,"given":"Paul M.","family":"Barr","sequence":"additional","affiliation":[{"name":"6University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9188-5008","authenticated-orcid":false,"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[{"name":"7Huntsman Cancer Institute at University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"8Dana Farber\/Partners CancerCare, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Lozanski","sequence":"additional","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-5562","authenticated-orcid":false,"given":"James","family":"Blachly","sequence":"additional","affiliation":[{"name":"1The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa","family":"Nattam","sequence":"additional","affiliation":[{"name":"9Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3203","authenticated-orcid":false,"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"10University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-2189","authenticated-orcid":false,"given":"Harry","family":"Erba","sequence":"additional","affiliation":[{"name":"5Duke Cancer Institute, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Luger","sequence":"additional","affiliation":[{"name":"11Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[{"name":"12Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kuzma","sequence":"additional","affiliation":[{"name":"13First Health of the Carolinas Cancer Center, Southeast Clinical Oncology Research Consortium, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"14Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-1699","authenticated-orcid":false,"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[{"name":"15Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Dinner","sequence":"additional","affiliation":[{"name":"16Division of Hematology and Oncology, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"8Dana Farber\/Partners CancerCare, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey","family":"Uy","sequence":"additional","affiliation":[{"name":"4Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"10University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra J.","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"2Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN"},{"name":"17Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"18University of Cincinnati Cancer Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"26","key":"2024041815203230300_bib1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024041815203230300_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"2024041815203230300_bib3","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8 years follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2024041815203230300_bib4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"2024041815203230300_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2013.1.158","article-title":"Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers","volume":"2013","author":"Shanafelt","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"22","key":"2024041815203230300_bib6","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2024041815203230300_bib7","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"2024041815203230300_bib8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"2024041815203230300_bib9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"2024041815203230300_bib10","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"446","key":"2024041815203230300_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"20","key":"2024041815203230300_bib12","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.2011.39.3090","article-title":"Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia","volume":"30","author":"Claus","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024041815203230300_bib13","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"2024041815203230300_bib14","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2024041815203230300_bib15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"2024041815203230300_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"9665","key":"2024041815203230300_bib17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(09)60443-8","article-title":"Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study","volume":"373","author":"Schnabel","year":"2009","journal-title":"Lancet"},{"issue":"36","key":"2024041815203230300_bib18","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1093\/eurheartj\/ehad375","article-title":"New-onset atrial fibrillation prediction: the HARMS2-AF risk score","volume":"44","author":"Segan","year":"2023","journal-title":"Eur Heart J"},{"issue":"31","key":"2024041815203230300_bib19","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024041815203230300_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or\u00a0refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"}],"updated-by":[{"DOI":"10.1182\/blood.2024027930","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/16\/1616\/2222266\/blood_bld-2023-021959-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/16\/1616\/2222266\/blood_bld-2023-021959-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T11:20:44Z","timestamp":1713439244000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/16\/1616\/514562\/Follow-up-from-the-A041202-study-shows-continued"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,4,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021959","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}